Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a ...

The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

Dr. Reddy's Laboratories Limited RDY reported first-quarter fiscal 2026 earnings of 20 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 18 cents. The company ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), ...

Biosimilars and Biologics Market Driven by aging populations and patent cliffs, the biosimilars & biologics market will grow from ~$531B in ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.

Dr. Reddy's reports Q1 earnings on July 23. before market open. Over the last 1 year, RDY has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time.

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating ...